Castle Biosciences
CSTL
182 hedge funds and large institutions have $1.52B invested in Castle Biosciences in 2021 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 78 increasing their positions, 45 reducing their positions, and 29 closing their positions.
237% more call options, than puts
Call options by funds: $7.33M | Put options by funds: $2.18M
73% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 45
28% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 29
4% more funds holding
Funds holding: 175 → 182 (+7)
4% more capital invested
Capital invested by funds: $1.46B → $1.52B (+$62.3M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.35% less ownership
Funds ownership: 85.38% → 83.03% (-2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$32.3M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$29.4M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$29.4M |
| 4 |
BlackRock
New York
|
+$21.7M |
| 5 |
ZCI
Zevenbergen Capital Investments
Edmonds,
Washington
|
+$17.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$68.5M |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$62.7M |
| 3 |
Select Equity Group
New York
|
-$24.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$22.1M |
| 5 |
Millennium Management
New York
|
-$17.1M |
CSTL Hedge Fund Activity: Q2 2021 in Review
182 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q2 2021, worth a combined $1.52B — up 4.3% from $1.46B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new CSTL positions and 29 closed out — a net gain of 8 holders — while 78 added to existing stakes and 45 trimmed.
The largest buyer was Macquarie Group, adding an estimated $32.3M. The largest seller was Matrix Capital Management Company, exiting entirely with an estimated $68.5M sold.
- 182 institutional investors held Castle Biosciences (CSTL) as of Q2 2021, up from 175 in Q1 2021.
- Funds reported $1.52B of Castle Biosciences stock for Q2 2021, up 4.3% quarter-over-quarter.
- 37 funds opened new Castle Biosciences positions in Q2 2021 and 29 closed out, a net change of +8 holders.
- The largest Castle Biosciences buyer in Q2 2021 was Macquarie Group, an estimated $32.3M added.
- The largest Castle Biosciences seller in Q2 2021 was Matrix Capital Management Company, an estimated $68.5M sold.
Based on aggregated 13F filings for Q2 2021.